Perfluorohexyloctane

Last updated

Perfluorohexyloctane
Perfluorohexyloctane.svg
Clinical data
Trade names Evotears
Miebo ( /ˈmaɪboʊ/ MY-bow)
Novatears
Other namesNOV03; 1-(perfluorohexyl)octane
AHFS/Drugs.com Monograph
MedlinePlus a623054
License data
Routes of
administration 		Eye drops
ATC code
  • None
Legal status
Legal status
Identifiers
  • 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluorotetradecane
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
CompTox Dashboard (EPA)
Chemical and physical data
Formula C14H17F13
Molar mass 432.269 g·mol−1
3D model (JSmol)
  • CCCCCCCCC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F
  • InChI=1S/C14H17F13/c1-2-3-4-5-6-7-8-9(15,16)10(17,18)11(19,20)12(21,22)13(23,24)14(25,26)27/h2-8H2,1H3
  • Key:WRYIIOKOQSICTB-UHFFFAOYSA-N

Perfluorohexyloctane (branded as Evotears, Miebo, [a] and Novatears, among others) is a medication used for the treatment of dry eye disease. [4] It is a semifluorinated alkane. [4]

Contents

Perfluorohexyloctane has been available in multiple markets since 2015 under the brand names Evotears and Novatears, [5] and was additionally approved for medical use in the United States in May 2023 under the brand name Miebo. [4] [6] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. [7]

Medical uses

Perfluorohexyloctane is indicated for the treatment of the signs and symptoms of dry eye disease. [4] [8] [9]

Availability

Perfluorohexyloctane is sold as an over-the-counter medication under the brand names Evotears and Novatears in multiple countries, [10] costing around NZ$34.00, A$30, and €30 for a one-month supply.

In the US, perfluorohexyloctane is sold under the brand name Miebo; a prescription is required.

See also

Notes and references

  1. ↑ "Notice: Multiple additions to the Prescription Drug List (PDL) [2024-10-18]". Health Canada . 18 October 2024. Retrieved 25 October 2024.
  2. ↑ "Miebo product information". Health Canada . 4 September 2024. Retrieved 27 December 2024.
  3. ↑ "Regulatory Decision Summary for Miebo". Drug and Health Products Portal. 4 September 2024. Retrieved 27 December 2024.
  4. 1 2 3 4 5 "Miebo- perfluorohexyloctane solution". DailyMed. 18 May 2023. Retrieved 8 June 2023.
  5. ↑ "URSAPHARM GmbH and Novaliq GmbH Announce European Partnership Agreement" (Press release). Retrieved 15 February 2024.
  6. ↑ "Bausch + Lomb and Novaliq Announce FDA Approval of Miebo (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of the Signs and Symptoms of Dry Eye Disease" (Press release). Bausch + Lomb Corporation. 18 May 2023. Retrieved 8 June 2023– via Business Wire.
  7. ↑ New Drug Therapy Approvals 2023. U.S. Food and Drug Administration (FDA) (Report). January 2024. Archived from the original (PDF) on 10 January 2024. Retrieved 9 January 2024.
  8. ↑ Ballesteros-Sánchez A, De-Hita-Cantalejo C, Sánchez-González MC, Jansone-Langine Z, de Sotomayor MA, Culig J, et al. (October 2023). "Perfluorohexyloctane in dry eye disease: A systematic review of its efficacy and safety as a novel therapeutic agent". The Ocular Surface. 30: 254–262. doi:10.1016/j.jtos.2023.10.001. hdl: 11441/151762 . PMID   37813152. S2CID   263802332.
  9. ↑ Sheppard JD, Evans DG, Protzko EE (November 2023). "A review of the first anti-evaporative prescription treatment for dry eye disease: perfluorohexyloctane ophthalmic solution". The American Journal of Managed Care. 29 (14 Suppl): S251 –S259. doi: 10.37765/ajmc.2023.89464 . PMID   37930231. S2CID   265032840.
  10. ↑ "In Australia, NovaTears Eye Drops Are Available on the Pharmaceutical Benefits Scheme (PBS) from Now On" (Press release). Retrieved 15 February 2024.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.